The central obstacle in solid tumor CAR T therapy has always been target selection. The therapy works by collecting a patient’s own T cells, genetically engineering them to recognize a specific protein on the surface of cancer cells, and reinfusing them so they hunt down and destroy anything bearing that molecular signature. In blood cancers, this is relatively straightforward because malignant B cells display molecules such as CD19 that are dispensable elsewhere in the body. Solid tumors are different. Most of their defining abnormalities hide inside the cell, driven by mutated or fused genes operating in the nucleus, while the proteins displayed on the cell surface tend to be shared with healthy tissues. Attacking them risks catastrophic off-tumor toxicity, and tumors that do express a target often do so unevenly, allowing antigen-negative cells to survive and seed relapse.

The research team approached this problem from a different angle: instead of searching for surface proteins common to broad cancer types, they looked for surface proteins that are directly commanded into existence by the specific gene fusions that drive certain rare cancers. Alveolar soft-part sarcoma, or ASPS, is a striking example. This aggressive sarcoma, which disproportionately strikes adolescents and young adults, is caused by a chromosome rearrangement that fuses the TFE3 transcription factor gene to the ASPSCR1 gene. Translocation renal cell carcinoma, similarly, arises from fusions involving MiT/TFE-family transcription factors such as TFE3 or TFEB. Because these fusion proteins are aberrant transcription factors, they rewire the cell’s gene expression program wholesale, and the investigators reasoned that this rewiring might force cancer cells to display unique combinations of surface molecules.

Using gene expression profiling across primary and relapsed tumor samples, the team identified glycoprotein NMB, or GPNMB, as a molecule that fits the bill. GPNMB is a transmembrane glycoprotein that in these fusion-driven cancers is expressed at high levels, with striking uniformity across tumor cells and remarkable stability over time. In ASPS and translocation renal cell carcinoma samples, including tumors that had relapsed after prior therapies, essentially every malignant cell carried GPNMB on its surface. This homogeneity is exactly what a CAR T target needs, because it denies tumor cells the escape route of simply switching the target off. Equally important, GPNMB expression in normal tissues is low and restricted, raising the prospect of a workable therapeutic window.

With the target validated, the researchers engineered a CAR T cell product they named GCAR1. The construct couples an antibody-derived recognition domain that binds GPNMB to intracellular signaling modules that activate the T cell upon contact, triggering killing of the target cell and proliferation of the engineered population. In the laboratory, GCAR1 cells showed potent, selective cytotoxicity against patient-derived tumor cells, lysing GPNMB-positive cancer cells while sparing matched normal cells that lacked the protein. The activity extended beyond flat cultures of cells into three-dimensional patient-derived organoids, which better recapitulate the architecture and drug resistance of real tumors, and into xenograft models in which human tumors were implanted in immunodeficient mice. In those animal models, GCAR1 infusions produced marked tumor control, establishing preclinical proof that the approach could work in living tissue.

The pivotal step came with the launch of a first-in-human, open-label, individual-participant clinical trial, registered as NCT07104682, designed to test GCAR1 in patients with relapsed or refractory fusion-driven solid tumors. The study reported here includes an interim analysis of a participant with metastatic ASPS whose disease had progressed despite standard treatment. Following lymphodepleting chemotherapy to clear space for the engineered cells, the patient received a single infusion of GCAR1. The clinical response, while not a complete remission, was notable: imaging showed stable disease sustained for up to three months, and, strikingly, many of the patient’s non-target lesions, smaller metastatic deposits not formally measured as primary endpoints, resolved entirely on follow-up scans. In a cancer as relentless as ASPS, with few effective systemic options and a median survival historically measured in a few years from diagnosis, even disease stabilization with lesion regression represents a meaningful clinical signal.

Just as important as the efficacy signal was the safety profile. GCAR1 was well tolerated, without the severe cytokine release syndrome, neurotoxicity, or on-target off-tumor organ damage that has plagued some solid tumor CAR programs. The engineered cells were detectable in the patient’s peripheral blood for about a month after infusion, expanding as a polyclonal population, meaning that multiple distinct T cell clones carrying the receptor expanded in parallel rather than a single clone dominating. Polyclonal persistence is generally viewed favorably, as it suggests a robust, diverse immune response less vulnerable to outgrowth of tumor variants that could evade any single clone. The one-month persistence window is also consistent with a controlled, self-limited therapy, which may explain the clean toxicity profile even against a target like GPNMB that has low-level normal tissue expression.

The study did not stop at the celebration of a response, however. One lesion in the patient proved treatment-resistant, and the team subjected it to an advanced molecular interrogation known as spatial transcriptomics, a technique that maps which genes are active at precise locations within intact tissue. The analysis revealed that the resistant lesion harbored immunosuppressive niches, microanatomical pockets enriched for pathways and cell types that suppress T cell function, effectively creating local sanctuaries where the CAR T cells could not operate even when they reached the tumor. This finding transforms an apparent failure into a roadmap: resistance, in this case, was not about loss of the GPNMB target but about the tumor microenvironment building walls around the attacking cells.

That mechanistic insight pointed directly at a rational combination strategy. Immune checkpoint blockade, the class of drugs that includes antibodies against molecules such as PD-1 and its ligand PD-L1, works by releasing molecular brakes that tumors place on T cells. The researchers tested whether combining checkpoint blockade with GCAR1 would overcome the immunosuppressive niches, and in a xenograft model the combination produced synergy, with the two modalities together controlling tumors more effectively than either alone. For a translational program, this is a crucial result, because checkpoint inhibitors are already approved, widely available, and clinically familiar. A future trial testing GCAR1 alongside checkpoint blockade is an obvious and achievable next step, and the preclinical synergy data provide the justification.

The broader conceptual contribution of the study may ultimately matter more than any single clinical result. The MiT/TFE-family fusion proteins that drive ASPS and translocation renal cell carcinoma are master regulators, and the demonstration that their activity can be exploited through a surface readout like GPNMB establishes a general paradigm: oncogenic gene fusions, though intracellular and classically considered undruggable, can be converted into actionable surface targets by mapping the transcriptional programs they impose. The same strategy could in principle be extended to other fusion-driven cancers, a category that includes many pediatric sarcomas, leukemias, and carcinomas for which targeted drugs remain elusive. Rather than trying to inhibit an undruggable fusion protein directly, clinicians could train a patient’s immune system to recognize the distinctive surface signature that the fusion creates.

Challenges remain before GCAR1 or its successors become standard care. The clinical experience so far involves a single participant in an interim analysis, and larger cohorts will be needed to confirm response rates, define the optimal dosing, and fully characterize toxicities. The three-month duration of disease control, while encouraging, will need to extend into durable remissions, likely through combinations with checkpoint inhibitors or other microenvironment-modulating agents suggested by the spatial transcriptomics findings. Questions about whether resistance can emerge through GPNMB loss in other patients, and whether GPNMB expression levels in normal tissues vary enough between individuals to cause occasional toxicity, will require larger datasets. Nevertheless, the trajectory from target discovery through organoid and xenograft validation to a controlled, tolerated, clinically active infusion in a patient with one of oncology’s most feared sarcomas has been completed in a single study, a bench-to-bedside arc that few experimental therapies achieve so cleanly. For patients with ASPS, translocation renal cell carcinoma, and other fusion-driven solid tumors, the message is that the wall separating CAR T success in blood cancers from success in solid tumors is no longer impenetrable, and the first engineered cells are already through it.

Chimeric antigen receptors function by equipping T cells with synthetic receptors that recognize tumor-specific antigens. The receptor features an extracellular antigen-binding domain, typically derived from antibody fragments, enabling exquisite specificity to cancer cell surface markers. Detection of the target antigen triggers intracellular signaling cascades initiated by the CD3-ζ domain combined with co-stimulatory components such as CD28, prompting cytotoxic T cell activation and elimination of malignant cells. While potent, this design is irreversible once activated, which can lead to unrestrained T cell activity, causing on-target, off-tumor toxicities and cytokine release syndromes.

The novel technology developed by Irving, Giordano Attianese, and colleagues enhances control over CAR-T cells via a ‘drug-regulated off-switch protein-protein interaction CAR’ (DROP-CAR) that modulates receptor integrity at the cell surface. This system does not rely on degrading CAR components or inducing CAR-T cell death, as previous off-switch designs did. Instead, it harnesses a finely engineered protein interface consisting entirely of human-derived elements, thus minimizing immunogenicity. The extracellular domain includes a computationally designed human protein, dubbed dmLD3, which binds BCL-2 with exceptional affinity. The CAR’s antigen-binding moiety is appended with a complementary BCL-2 fragment. In the assembled complex, the dmLD3 and BCL-2 components maintain CAR integrity through spontaneous protein-protein interactions.

Venetoclax, an FDA-approved cancer drug known for its high-affinity binding to BCL-2, serves as the molecular remote control in this system. Administration of venetoclax competitively disrupts the dmLD3-BCL-2 interaction, causing the extracellular CAR architecture to dissociate and the receptor to disassemble, effectively silencing the CAR-T cell’s tumor-targeting function. Crucially, the CAR receptors then swiftly reassemble upon venetoclax withdrawal, restoring cytotoxic activity. This reversible mechanism allows precise temporal modulation of CAR-T cell functionality without triggering apoptosis or cell removal, preserving the therapeutic cell population across treatment cycles.

From a mechanistic perspective, this innovation exploits a novel strategy whereby the critical ligand-binding interface of the CAR is placed under direct drug inducible control on the cell surface, which represents a significant departure from intracellular control systems that target signaling components. This extracellular targeting permits instantaneous and direct regulation of tumor cell engagement, thereby avoiding downstream signaling perturbations that could have off-target effects or induce premature T cell exhaustion. The integration of entirely human protein constituents promises improved biocompatibility and clinical translatability.

One of the challenges that continuous CAR-T cell activity faces is antigen-driven exhaustion, a phenomenon whereby persistent stimulation in the immunosuppressive tumor microenvironment leads to a dysfunctional T cell state, marked by epigenetic and transcriptomic remodeling that curb effector functions. The DROP-CAR design provides a potential solution by enabling treatment protocols in which CAR-T cells can be transiently ‘paused,’ allowing them to rest and recover function before reactivation. Such temporal control could extend the durability and efficacy of CAR-T therapies against solid tumors, which often exhibit highly suppressive milieus.

The strategic use of venetoclax as both a therapeutic agent and an off-switch control element is ingenious, leveraging its established safety profile and clinical experience. Venetoclax’s known pharmacokinetics and dosage guidelines streamline potential regulatory hurdles, facilitating rapid translation from preclinical models to human trials. Moreover, unlike previous CAR modulation approaches that used exogenous small molecules or induced degradation pathways, this system’s non-immunosuppressive drug does not compromise host immunity, maintaining a favorable toxicity profile.

Preclinical validation in murine cancer models affirmed that DROP-CAR T cells retain robust antitumor efficacy when active and can be effectively switched off and back on with venetoclax dosing cycles. This on-demand control mitigates risks associated with systemic cytokine storms and off-target cytotoxicity without sacrificing anti-tumor potency. The researchers emphasize that this technology could democratize CAR-T therapy by broadening its applicability beyond hematologic malignancies to solid tumors and enhancing the safety margin of treatments.

This pioneering work signifies a conceptual leap in synthetic immunology by applying computational protein design to engineer high-affinity modulatable interfaces, integrating them into living cell therapies. The reversible ‘off-switch’ paradigm parallels the sophistication of electronic devices in continuously fine-tuning outputs to meet real-time physiological demands, reflecting a new frontier in precision immunotherapy. By empowering clinicians with this level of control, it may soon become possible to customize CAR-T regimens on a patient-specific basis, dynamically adjusting therapeutic intensity in response to individual tumor burden and immune status.

As the field of engineered cellular therapies continues to mature, such controllable CAR systems represent a paradigm shift that addresses some of the fundamental limitations restraining the broader success of CAR-T cells against complex, heterogeneous solid tumors. The ability to govern CAR function externally, without sacrificing cell viability or inducing immunosuppression, could transform the clinical management of cancer, improving both efficacy and safety. The work from Ludwig Lausanne and EPFL exemplifies translational excellence, wherein molecular engineering, drug repurposing, and immunobiology converge to realize next-generation cancer treatments.

Overall, this study provides a robust platform for future clinical investigations, with the potential to modulate CAR-T cell activity precisely, reduce toxicities, extend therapeutic windows, and ultimately improve patient outcomes in oncology. Given the serious unmet needs in solid tumor immunotherapy and the well-documented limitations of current CAR-T technologies, the DROP-CAR approach marks a substantial advancement toward safer and more adaptable cellular therapies.

Subject of Research:
Cancer Immunotherapy, CAR-T Cell Engineering, Protein-Protein Interaction Modulation

Article Title:
Remote-Controlled OFF-Switch CAR-T Cells Enable Precise, Reversible Modulation of Antitumor Activity with Venetoclax

News Publication Date:
February 19, 2026

Web References:
https://www.nature.com/articles/s41589-026-02152-x

Image Credits:
Ludwig Cancer Research

Keywords:
Health and medicine, Cancer, Immunology, Immunotherapy

For decades, the immune system’s potential to combat cancer has been stymied by the tumor’s ability to evade immune detection and suppression of cytotoxic T cell responses. Central to this challenge is the identification of tumor-specific antigens that can serve as reliable flags for immune attack without collateral damage to normal tissues. The DKK1 protein, known for its involvement in various cellular pathways including Wnt signaling and bone remodeling, has recently emerged as a malignant biomarker due to its aberrant expression in numerous cancers. By focusing on the DKK1-A2 molecular complex, researchers have pinpointed a highly specific target that can be exploited by engineered immune cells designed to overcome the tumor’s stealth mechanisms.

The team employed advanced genetic engineering techniques to generate T cells capable of recognizing the precise conformation of the DKK1 peptide presented in conjunction with the human leukocyte antigen A2 (HLA-A2) on the surface of cancer cells. This is a sophisticated approach that leverages the natural process of antigen presentation, wherein short peptide fragments from intracellular proteins are displayed on HLA molecules, serving as an immunological signature. By engineering T cell receptors (TCRs) with enhanced affinity and specificity for the DKK1-A2 peptide complex, the researchers ensured heightened immune surveillance and cytotoxic activity strictly against malignant cells bearing this complex.

This tailored immunotherapy achieved remarkable efficacy in preclinical models encompassing both solid tumors and hematologic malignancies. The engineered T cells were able to infiltrate tumor microenvironments, recognize DKK1-A2 positive cells, and induce targeted cell death without eliciting off-target toxicity. Importantly, the specificity of these TCR-engineered T cells mitigates the risk of adverse autoimmune reactions, which have been a considerable barrier in earlier, less discriminating immunotherapeutic strategies. The selective targeting of a shared yet tumor-associated antigen broadens the therapeutic scope across a variety of HLA-A2 positive cancers.

Underlying the success of this approach is a profound understanding of the structural biology of TCR-peptide-MHC interactions. High-resolution crystallography and computational modeling were leveraged to optimize the binding interface, ensuring that the engineered TCR engages the DKK1-A2 complex with a binding affinity sufficient to trigger T cell activation but calibrated to avoid excessive cross-reactivity. This rational design embodies the new generation of precision immunotherapy, where molecular-level insights translate directly into safer and more effective cellular therapies.

Beyond demonstrating tumor eradication in animal models, the study also explored the mechanistic basis of immune resistance and immune evasion in cancer. The DKK1 protein’s expression correlates with immunosuppressive tumor microenvironments, including modulation of myeloid-derived suppressor cells and regulatory T cells. By eliminating DKK1-expressing cancer cells, these engineered T cells not only cleared malignant populations but also alleviated immunosuppressive signaling, effectively remodeling the tumor milieu into one conducive to sustained immune control.

The translational promise of this research is substantial. Given the prevalence of HLA-A2 alleles in diverse populations, a wide patient demographic stands to benefit from therapies targeting the DKK1-A2 complex. The platform also holds potential for rapid adaptability, enabling similar engineering of T cells against other peptide-HLA complexes implicated in different cancer subtypes. This modularity could accelerate the pipeline of personalized TCR-based therapies, democratizing access to highly individualized cancer treatment regimens.

Collaboration between immunologists, structural biologists, and clinical oncologists was pivotal in advancing this multidisciplinary study. The consortium harnessed cutting-edge bioengineering, in vitro assays, and in vivo tumor models, followed by rigorous safety and efficacy evaluations. This integrated effort underscores a paradigm wherein fundamental discoveries in tumor immunology dovetail with clinical innovation to forge new therapeutic frontiers.

Furthermore, the engineered T cells demonstrated persistence and robust expansion in vivo, key attributes for durable antitumor immunity. Their capacity to form immunological memory cells suggests long-term surveillance against tumor relapse, a notable advantage over conventional therapies often plagued by recurrence. Safety assessments revealed manageable cytokine release profiles, indicating that the intervention’s potent immunological effects can be contained clinically without triggering severe systemic inflammation.

As this technology progresses toward early-phase human clinical trials, regulatory and manufacturing challenges loom. However, the study’s demonstration of scalable generation of high-purity engineered T cell products via viral vector transduction and closed-system bioreactor culture lays the groundwork for clinical translation. These practical advances may shorten the journey from bench to bedside, enabling patients with refractory cancers to access transformative therapies in the near future.

The implications of targeting the DKK1-A2 complex extend beyond therapy alone. This research opens avenues for companion diagnostic development, wherein detection of DKK1-A2 expression on tumor biopsies could serve as a biomarker for patient stratification and treatment monitoring. Such precision medicine approaches promise to optimize therapeutic outcomes by aligning patient molecular profiles with the most appropriate engineered cellular therapies.

In sum, this landmark study heralds a new chapter in engineered T cell immunotherapy, innovatively merging molecular targeting specificity with functional efficacy against a historically challenging cohort of cancers. By allying structural insight with immunological engineering, the researchers have unlocked a potent weapon against malignancies expressing the DKK1-A2 complex, signaling a hopeful future for patients battling solid and hematologic tumors resistant to existing modalities.

This pioneering work not only enriches the armamentarium of cancer immunotherapy but also exemplifies the transformative power of next-generation T cell engineering. As the oncology community eagerly anticipates the clinical evaluation of these engineered T cells, this research stands as a compelling testament to the potential of precision immunotherapy to deliver curative outcomes in cancer.

Subject of Research: Engineered T cell immunotherapy targeting the Dickkopf-1 (DKK1)-A2 complex to treat HLA-A2 positive solid and hematologic cancers.

Article Title: T cells engineered against Dickkopf-1-A2 complex can be used to treat HLA-A2⁺ solid and hematologic cancers.

Article References:
Zhang, Y., Xiong, W., Qian, J. et al. T cells engineered against Dickkopf-1-A2 complex can be used to treat HLA-A2⁺ solid and hematologic cancers. Nat Commun (2026). https://doi.org/10.1038/s41467-026-69621-8

Image Credits: AI Generated